Patents Issued in May 2, 2017
  • Patent number: 9636283
    Abstract: A multi-phase personal cleansing composition comprising: (a) a structured aqueous cleansing phase comprising a surfactant and water; and (b) at least one additional, non-lamellar aqueous phase; wherein at least one of said structured aqueous cleansing phase and said additional aqueous phase comprises at least one non-migrating colorant, said non-migrating colorant comprising a cLogP value of at least about 2; and wherein said structured aqueous cleansing phase and said additional aqueous phase are packaged in physical contact with one another.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: May 2, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Mannie Lee Clapp, Karl Shiqing Wei, Christopher Garrett Anderson
  • Patent number: 9636284
    Abstract: The present invention relates generally to oral care compositions, and more specifically to oral care compositions suitable for cleaning the oral cavity. Methods of use are also disclosed.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: May 2, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Lauren Vierling, Dexter M. Williams, Saroja Narasimhan, E. Eric Engelman, Joseph J. LiBrizzi
  • Patent number: 9636285
    Abstract: An emulsion composition includes a compound having a diaminopyrimidine skeleton, at least one fatty acid component selected from the group consisting of a fatty acid having a total carbon number of 14 or more and a salt thereof, and an aqueous medium in an amount of 50% by mass or more with respect to the mass of the emulsion composition. The total amount of monohydric alcohol having a total carbon number of 3 or less and dihydric alcohol having a total carbon number of 3 or less is less than 10% by mass with respect to the mass of the emulsion composition. The emulsion composition has a pH of 6.5 or more.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: May 2, 2017
    Assignee: FUJIFILM Corporation
    Inventors: Shinichi Hashimoto, Shigetomo Tsujihata
  • Patent number: 9636286
    Abstract: Compositions containing a quaternary ammonium compound (QAC) “active” to provide an antimicrobial property, a quaternized phospholipid which provides a reduction in potential irritancy of other ingredients as well as foaming and cleansing properties, a second non-ionic or amphoteric surfactant (such as an alkyl amine oxide or linear alkyl polyglucoside) to provide increased foam volume and cleansing properties, a non-ionic or quaternized polymer (such as hydroxypropylmethylcellulose or hydroxypropyl guar hydroxypropyl trimonium chloride) which can provide thickening, foam structure and improved after-feel properties are described.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: May 2, 2017
    Assignee: Coloplast A/S
    Inventor: Heather Grundhofer
  • Patent number: 9636287
    Abstract: Compositions containing a solution of a polyfunctional aziridine component in a non-reactive solvent, and methods of applying such compositions to proteinaceous substrates, such as fingernails and toenails, to provide primed substrates which may be further coated.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: May 2, 2017
    Assignee: Mad River Science
    Inventor: Norman Polston
  • Patent number: 9636288
    Abstract: Agents for oxidatively dyeing keratinous fibers include, in a cosmetic carrier, as an oxidation dye precursor of the developer type, at least one compound of formula (I) as set forth herein, in which R1, R2 can stand independently of each other, for a hydrogen atom, different substituted alkyl groups, and/or different substituted acrylic groups, and Y stands for a hydroxyl group, an amino group, or a C1-C6 alkylamino group, with the proviso that at least one of the moieties from the group R1 and R2 does not stand for a hydrogen atom, and/or the physiologically compatible salt thereof.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: May 2, 2017
    Assignee: Henkel AG & Co. KGaA
    Inventors: Antje Gebert-Schwarzwaelder, Helmut Giesa, Melanie Moch
  • Patent number: 9636289
    Abstract: The present invention provides a method for preventing or treating hair loss or promoting hair growth, comprising secoiridoid glucoside derivatives or hydrolysate thereof as active ingredients. The present invention not only includes natural compounds as an active ingredient without side effects of the long-term treatment in a chronic disease hair loss, but also shows excellent effects for promoting hair growth with stable efficacy. Therefore, the present invention may be used as an effective pharmaceutical, cosmetic or functional food composition for preventing or treating hair loss or promoting hair growth.
    Type: Grant
    Filed: July 8, 2013
    Date of Patent: May 2, 2017
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventor: Tae Sun Park
  • Patent number: 9636290
    Abstract: The invention relates to cosmetic or dermatological compositions containing mannoproteins as an active ingredient and/or adjuvant, to the use of said cosmetic or dermatological compositions and to cosmetic treatment methods.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: May 2, 2017
    Assignee: LESAFFRE ET COMPAGNIE
    Inventors: Peter Jüsten, Dominique Marie Noëlle Borreill
  • Patent number: 9636291
    Abstract: The present invention generally relates to compositions and methods for transdermal delivery, and treatment of hair related conditions. The compositions can be used in a variety of applications, including causing or promoting hair growth and/or hair pigmentation. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the scalp, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: May 2, 2017
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9636292
    Abstract: Topical skin care composition for night use containing a combination of stabilized anti-oxidants, oat derived avenanthramides, retinol-like compounds and biofunctional peptides and other optional ingredients for topical application for the treatment and prevention of skin damage due to environmental factors.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 2, 2017
    Assignee: Truth Aesthetics LLC
    Inventors: Sara Sweeney, Fred H. Khoury
  • Patent number: 9636293
    Abstract: A nail compositions comprising at least one photo-curable polymer dispersed in water (latex), at least one non-photo-curable polymer dispersed in water (latex), at least one photo-initiator, optionally at least one plasticizer, optionally a colorant, and water are provided. Also provided are nail composition systems and kits comprising the nail compositions of the invention together with a base coat composition and/or a top coat composition.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: May 2, 2017
    Assignee: L'ORÉAL
    Inventors: Aline Aude Guimont, Chunhua Li, Xianzhi Zhou, Hy Si Bui, Jean-Thierry Simonnet
  • Patent number: 9636294
    Abstract: A mascara composition including an olefin/acrylate grafted polymer and a styrene/acrylates copolymer. Preferably, the ratio of the weight amount of the olefin/acrylate grafted polymer to the weight amount of the styrene/acrylates copolymer is from about 1:3 to about 4:1.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: May 2, 2017
    Assignee: L'OREAL
    Inventors: Hy Si Bui, Christopher Pang
  • Patent number: 9636295
    Abstract: The present invention relates to a new cosmetic product for treating keratinous materials, particularly hair, to the method for preparing the cosmetic product, and to a cosmetic method for the care of keratinous material using these compositions.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: May 2, 2017
    Assignee: GUILHERME BELTRÃO DE ALMEIDA
    Inventor: Guilherme Beltrão De Almeida
  • Patent number: 9636296
    Abstract: The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: May 2, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Longsheng Hu, Virginia Streusand Goldman, Josephine A. Minerva, Susan Wendling
  • Patent number: 9636297
    Abstract: The present invention relates to a method for the cosmetic treatment of a keratin material comprising at least the steps of: (a) having available a lyophilizate containing at least one live or inactivated, physiologically acceptable microorganism, one of its metabolites or one of its fractions and at least one surfactant with an HLB greater than or equal to 12, (b) having available a physiologically acceptable medium, separate from the said lyophilizate, (c) bringing the said lyophilizate extemporaneously into contact with the said medium under conditions favorable for the solubilization and/or dispersion of the said lyophilizate in the said medium, and (d) bringing the mixture obtained in the preceding step into contact with the said keratin material. It further relates to a lyophilizate as defined above.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 2, 2017
    Assignee: L'OREAL
    Inventors: Jean-Thierry Simonnet, Karine Lucet-Levannier
  • Patent number: 9636298
    Abstract: The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: May 2, 2017
    Inventors: Alain Ajamian, Yves Andre Chantigny, Arkadii Vaisburg, Franck Raeppel, Stephane Raeppel, Robert Deziel
  • Patent number: 9636299
    Abstract: Compositions useful for treatment of retinal pathologies, including diabetic retinopathy, and methods of making and using said compositions, are provided.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 2, 2017
    Assignee: XAVIER UNIVERSITY OF LOUISIANA
    Inventor: Partha S. Bhattacharjee
  • Patent number: 9636300
    Abstract: A composition comprising racecadotril, at least one surfactant and a lipid.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: May 2, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventor: Der-Yang Lee
  • Patent number: 9636301
    Abstract: The present invention provides a novel in vitro release assay for the accurate, reproducible quantitation of vincristine sulfate release from liposomes.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: May 2, 2017
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventor: Thomas Philip Weber
  • Patent number: 9636302
    Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 2, 2017
    Assignee: AXOLABS GMBH
    Inventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
  • Patent number: 9636303
    Abstract: A pharmaceutical dosage form and method of using same, the pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); a physiologically acceptable polymer (B) obtainable by polymerization of a monomer composition comprising an ethylenically unsaturated monomer bearing an anionic functional group, in protonated form or a physiologically acceptable salt thereof; a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the polymer (B) and the polyalkylene oxide (C).
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: May 2, 2017
    Assignee: GRUENENTHAL GMBH
    Inventors: Lutz Barnscheid, Sebastian Schwier, Johannes Bartholomäus
  • Patent number: 9636304
    Abstract: A solid oral pharmaceutical composition in the form of tablets including:—a first solid oral pharmaceutical formulation in the form of at least one micro-tablet, the micro-tablet consisting of a core including at least one Krebs cycle precursor salt as active ingredient, and of a coating including at least one coating agent, and—a second oral pharmaceutical formulation in the form of at least one mini-tablet, the mini-tablet consisting of a core including at least one bicarbonate salt as active ingredient and at least one prolonged-release matrix, and of a coating including at least one coating agent. The use thereof as a medicament, in particular in the treatment and/or prevention of cystinuria.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: May 2, 2017
    Assignee: ADVICENNE
    Inventors: Catherine Guittet, Luc-Andre Granier, Caroline Roussel-Maupetit
  • Patent number: 9636305
    Abstract: A solid oral dosage form includes a core comprising a non-ionic polymer matrix, a first amount of a first antiemetic drug or a pharmaceutically acceptable salt thereof dispersed within the matrix, and a salt dispersed within the matrix; a first seal coat of a non-ionic polymer matrix surrounding the core; and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of a second antiemetic drug or a pharmaceutically acceptable salt thereof dispersed therein, wherein the drug layer is sufficiently designed to release the second amount of the antiemetic drug over a period of at least 1 hour, wherein the solid oral dosage form is sufficiently designed to release the first amount of the first antiemetic drug and the second amount of the second antiemetic drug over a minimum period of 16 hours.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 2, 2017
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday
  • Patent number: 9636306
    Abstract: An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate. In another embodiment, the oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a population of a pharmaceutical active; a population of a basic substance; a population of enteric coated pharmaceutical active; and a population of enteric coated basic substance. The composition can provide multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: May 2, 2017
    Assignee: INTELLIPHARMACEUTICS CORP.
    Inventors: Isa Odidi, Amina Odidi
  • Patent number: 9636307
    Abstract: The invention provides coated particles with taste-masked N-acetylcysteine. The particles comprise a core with the active ingredient and a coating comprising a triglyceride and a surfactant. The particles exhibit rapid drug release and a stable release profile. Moreover, the invention provides a hot-melt coating method for manufacturing such particles, and pharmaceutical compositions comprising the particles. The method allows the coating of core particles at moderate temperatures, thereby preventing the degradation of the thermolabile active ingredient.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: May 2, 2017
    Assignee: HERMES ARZNEIMITTEL GMBH
    Inventors: Karin Becker, Detlev Haack, Sharareh Salar Behzadi, Andreas Zimmer
  • Patent number: 9636308
    Abstract: A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: May 2, 2017
    Assignee: Oakwood Laboratories LLC
    Inventors: Tracy Richey, Bagavathikanun Chithambara Thanoo
  • Patent number: 9636309
    Abstract: Provided is a drug delivery composition comprising at least one polymer and at least one active agent; wherein the active agent is present in crystalline form on at least one region of an outer surface of the composition and wherein active agent surface content is adjusted to provide a selected active agent release profile.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: May 2, 2017
    Assignee: Micell Technologies, Inc.
    Inventors: James B. McClain, Charles Douglas Taylor, Wenda C. Carlyle
  • Patent number: 9636310
    Abstract: A method of increasing strength using a nutrient holding device (pedal device, hat band, necklace, locket, belt, etc.) which contains at least one nutrient which has the ability to stimulate reflex zones on the skin resulting in improved performance when worn during athletic endeavors (exercise).
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: May 2, 2017
    Inventor: Edward Ludwig Blendermann
  • Patent number: 9636311
    Abstract: A method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N?-di-1-Naphthylguanidine hydrochloride (NAGH); N,N?-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: May 2, 2017
    Assignee: University of South Florida
    Inventors: Keith R. Pennypacker, Alison Willing, Javier Cuevas, Jon C. Antilla, Michelle Cortes-Salva
  • Patent number: 9636312
    Abstract: Methods for treating the animal central nervous system for the effects of traumatic brain injury. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient suffering from traumatic brain injury. The effective amount of DFO is delivered directly to the patient's central nervous system for treating the traumatic brain injury.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: May 2, 2017
    Assignee: HealthPartners Research Foundation
    Inventors: William H. Frey, II, Samuel Scott Panter, Leah Ranae Bresin Hanson
  • Patent number: 9636313
    Abstract: Methods for treating the animal central nervous system against the effects of spinal cord injury, including associated cognitive, behavioral and physical impairments. Effective amounts of therapeutic agents are administered to the upper third of the patient's nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of a therapeutic agent is the iron chelator deferoxamine (DFO).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 2, 2017
    Assignee: HealthPartners Research Foundation
    Inventors: William H. Frey, II, Samuel Scott Panter, Leah Ranae Bresin Hanson
  • Patent number: 9636314
    Abstract: A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 2, 2017
    Assignee: Stevia Limited
    Inventors: Kjeld Hermansen, Soren Gregersen, Per Bendix Jeppesen
  • Patent number: 9636315
    Abstract: Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: May 2, 2017
    Assignee: Natural Alternatives International, Inc.
    Inventors: Roger Harris, John Wise
  • Patent number: 9636316
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on baclofen and acamprosate combination.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: May 2, 2017
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 9636317
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: May 2, 2017
    Assignee: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Patent number: 9636318
    Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: May 2, 2017
    Assignee: BANNER LIFE SCIENCES LLC
    Inventors: Jason M. Vaughn, Justin R. Hughey, Tanesha Roberts, Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
  • Patent number: 9636319
    Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 2, 2017
    Assignee: BANNER LIFE SCIENCES LLC
    Inventors: Jason M. Vaughn, Justin R. Hughey, Tanesha Roberts, Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
  • Patent number: 9636320
    Abstract: A method for treating skin cancer including the steps of applying an isothiocyanate functional surfactant to an area affected by skin cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 2, 2017
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9636321
    Abstract: Novel isohexides and pharmaceutical compositions containing the same as well as methods of using the same in the treatment of psoriasis.
    Type: Grant
    Filed: March 27, 2016
    Date of Patent: May 2, 2017
    Assignee: SYMBIONYX PHARMACEUTICALS INC.
    Inventors: Ratan K Chaudhuri, Krys Bojanowski
  • Patent number: 9636322
    Abstract: The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: May 2, 2017
    Assignee: Humanetics Corporation
    Inventors: Edmund Joseph Elder, Jr., Mark Joseph Sacchetti, Randall Joseph Tlachac, John L. Zenk
  • Patent number: 9636323
    Abstract: The present invention provides a method of treating cancer that overexpresses TopBP1 by administering to a patient suffering from the cancer with an effective amount of a small molecule inhibitor that binds the BRCT7/8 domain of TopBP1.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: May 2, 2017
    Assignee: Baylor College of Medicine
    Inventors: Weei-Chin Lin, Pinki Chowdhury, Gregory E. Lin, Kang Liu, Yongcheng Song, Fang-Tsyr Lin
  • Patent number: 9636324
    Abstract: Disclosed is use of andrographolide derivative as shown by general formula 1 in manufacture of medicaments for anti-hepatitis C virus, and preventing and treating immunological liver damage caused by virus infection and different chemical liver damage.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 2, 2017
    Assignee: Zhengzhou University
    Inventors: Guifu Dai, Jing Zhao, Haiwei Xu, Huanfei Liu, Zhenwei Wu, Di Wu, Jian Wu, Hongmin Liu
  • Patent number: 9636325
    Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 2, 2017
    Assignee: IXCELA, INC.
    Inventor: Wayne R. Matson
  • Patent number: 9636326
    Abstract: Degranulation suppressors are provided that are effective against allergic disease and osteoarthritis. The degranulation suppressors contain chlorophyll c.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: May 2, 2017
    Assignee: MARUHA NICHIRO CORPORATION
    Inventors: Hisashi Yoshioka, Akira Kamata, Tatsuya Konishi, Hiroshi Oda, Tadakazu Tamai
  • Patent number: 9636327
    Abstract: The present description relates to methods of administering effective amounts of an anti-arrhythmic agent, e.g., dantrolene, azumolene or a pharmaceutically acceptable salt thereof, for the acute treatment of cardiac arrhythmias, e.g., atrial fibrillation, premature ventricular contraction, ventricular tachycardia or ventricular fibrillation, and prevention of subsequent cardiac arrhythmias, wherein the methods effectuate a reduction in morbidity and mortality.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 2, 2017
    Assignee: University Health Network
    Inventor: Kumaraswamy Nanthakumar
  • Patent number: 9636328
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: May 2, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Patent number: 9636329
    Abstract: Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: May 2, 2017
    Assignee: Northwestern University
    Inventors: Malathy Shanmugam, Steven T. Rosen
  • Patent number: 9636330
    Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: May 2, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
  • Patent number: 9636331
    Abstract: Pharmaceutical compositions and methods for treating bacterial infections are disclosed.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: May 2, 2017
    Assignee: WOCKHARDT LIMITED
    Inventors: Mahesh Vithalbhai Patel, Sachin Bhagwat, Prasad Keshav Deshpande
  • Patent number: 9636332
    Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 2, 2017
    Assignee: CLEARSIDE BIOMEDICAL, INC.
    Inventors: Vladimir Zarnitsyn, Samirkumar Patel, Daniel White, Glenn Noronha, Brian Burke